Advancing treatment of genetic diseases through engineered tRNA therapeutics

#55555

Engineered transfer RNA (tRNA) therapeutics carry the potential to provide disease-modifying treatments for patients with genetic ‘Stop Codon’ Disease. David McCall, Senior Editor, BioInsights, speaks to William Kiesman, CTO, Alltrna, about his company’s pioneering work in the tRNA field, which is driven by recent advancements in machine learning (ML).

Please enter your email to access content Read now